Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716116 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Takeda.
- Active
- Registry status
- Phase 1
- Development phase
- 334
- Enrollment target
- 20
- Study locations
NCT02716116: Active Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Takeda.
NCT02716116 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Takeda. The registered enrollment target is 334 participants, roughly in line with the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02716116, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 334 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
Conditions Studied
Interventions
- DRUG TAK-788
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- Compassionate Cancer Care - Fountain Valley - Fountain Valley
- University of California San Diego Moores Cancer Center - La Jolla
- Pacific Shores Medical Group-Long Beach Elm - Long Beach
- Cancer and Blood Specialty Clinic - Los Alamitos
- University of California Irvine Health Chao Family Comprehensive Cancer Center - Orange
- Stanford Cancer Center - Palo Alto - Palo Alto
- SLO Oncology and Hematology Health Center - San Luis Obispo
- The Oncology Institute of Hope and Innovation - Whittier
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- The Oncology Institute of Hope and Innovation - West Tucson - Tucson
Alabama
- Brookwood Medical Center - Birmingham
Colorado
- University of Colorado Cancer Center - Aurora
Florida
- AdventHealth Orlando - Orlando
Georgia
- Winship Cancer Institute - Atlanta
Illinois
- The University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2016-06-16 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
What the registry record for NCT02716116 still lists
NCT02716116 is an interventional study that assigns participants to a tested intervention. The registered 334 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which TAK-788 is the first listed.
NCT02716116 names 20 study sites across 9 states, led by California, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT02716116 about?
NCT02716116 is a clinical study titled "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer". This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to...
What is the current status of trial NCT02716116?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 334 participants. The study started on 2016-06-16. Estimated completion is 2026-10-31.
What conditions does trial NCT02716116 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT02716116?
The interventions under investigation include: TAK-788 (DRUG).
Who is sponsoring clinical trial NCT02716116?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02716116 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02716116's enrollment target sits among peer trials
334 38th of 130 higher than 93 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
- NCT05722197 · 334 participants · NA
Assessment of Emotion Regulation Strategies Used When Suicidal
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI